India, March 20 -- Natco Pharma Ltd. is set to launch the generic version of Ozempic at a price that's 90% cheaper than the original created Novo Nordisk A/S, triggering a price war for weight-loss drugs in India as the patent for key ingredient semaglutide expires.

Priced at Rs.1,290 per month, Natco Pharma's multi-dose vial undercuts Novo Nordisk's original brand by roughly 90% as the first-of-its-kind vial format is ~70% cheaper than pen devices prevalent in this drug category. The drug has to be taken in combination with diet and exercise for patients with Type 2 Diabetes.

The Hyderabad-based drugmaker received approval from the Central Drugs Standard Control Organisation in February 2026 to manufacture and market the generic drug. ...